Cost containment analysis of childhood vaccination against varicella in Israel

Journal of Infection

Volumn 48, Issue 2, 2004, Pages 119-133

  Ginsberg, G M ^a   Somekh, E ^b,c  

^a MINISTRY OF HEALTH   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cost containment analysis; Vaccination; Varicella

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CALAMINE; CHICKENPOX VACCINE; PARACETAMOL; PLACEBO; VARICELLA ZOSTER VACCINE; VARILIX;

ABSENTEEISM; CHICKENPOX; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COUGHING; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ECONOMIC EVALUATION; FEMALE; FEVER; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; IMMUNIZATION; INCIDENCE; INJECTION SITE REACTION; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHARYNGITIS; REVIEW; RHINITIS; SIDE EFFECT; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

EID: 1642464881     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(03)00079-3     Document Type: Article

References (111)

1. Gershon AA. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis 1995;10:93-124.
2. Flalhaut A, Dreau H, Farran N, et al. Epidemiologie des malades transmissibles en medecine liberale: bilan du reseua sentinelles en 1996. BEH 1997;15:33-39.
3. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr 1997;130:79-86.
4. Choo PW, Donahue JG, Mason JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995;172: 706-712.
5. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: Part I. Cost of uncomplicated cases. Pediatrics 1999;104:1-6.
6. Preblud SR. Varicella: complications and costs. Pediatrics 1986;78:728-735.
7. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella program for US children. JAMA 1994;271: 375-381.
8. Guess MA, Broughton DD, Melton LJ, Kurland IT. Population-based studies of varicella complications. Pediatrics 1986; 78:723-727.
9. Wilkins EGL, Leen CLS, McKendrick MW, Carrington D. Management of chickenpox in the adult. J Infect 1998; 36(Suppl. 1):49-58.
10. Fairley CK, Miller E. Varicella-zoster virus eidemiology - a changing scene? J Infect Dis 1996;174(Suppl. 3): S314-S319.
11. Enders G, Miller E, Cradock-Wnnnatson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregrnancy: prospective study of 1739 cases. Lancet 1994;343:1548-1551.
12. Pastuzak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first weeks of pregnancy. N Engl J Med 1994;330:901-905.
13. Meyers JD. Congenital varicella in term infants: risk considered. J Infect Dis 1974;129:215-217.
14. Rusthoven JJ. The risk of varicella-zoster infections in different patient populations: a critical review. Transfus Med Rev 1994;8:96-116.
15. Holmes SJ, Reef S, Hadler SC, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45:1-36.
16. Aebi C, Ahmed A, Ramilo O. Bacterial complications of primary varicella in children. Clin Infect Dis 1996;23: 698-705.
17. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 1996;10:571-581.
18. CDC, Prevention of Varicella: Recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR 45: RR-11, Atlanta, GA: US Department of Health and Human Services; 1996.
19. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age specific incidence of chickenpox. Public Health Rep 1994;109:750-755.
20. Johnson CE, Stancin T, Fattlar D, Rome LP, Kumar ML. A long term prospective study of varicella vaccine in healthy children. Pediatrics 1997;100:761-766.
21. WHO, Weekly epidemiological record. Varicella vaccines. Geneva 1998;73:241-248.
22. Notifiable Infectious Diseases in Israel 1951-1995. Israel Ministry of Health. Epidemiology Department, Public Health Services. The Israel Center for Disease Control (ICDC). Publication No. 1, September 1996.
23. Varughese PV. Chickenpox in Canada. Can Med Assoc J 1988;138:133-134.
24. Takahashi M, Gershon AA. Varicella vaccine. In: Plotkin SA, Mortimor EA, editors. Vaccines. Philadelphia, PA: WB Saunders; 1994. p. 387-418.
25. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 1996;174(Suppl. 3):S330-S334.
26. American Academy of Pediatrics, Committee on infectious diseases. Varicella vaccine update. Pediatrics 2000;10: 136-141.
27. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty year old follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94: 524-536.
28. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VAVIRAX) in healthy children and adolescents: results from clinical trials 1987-1989. Pediatrics 1991;87:604-610.
29. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. Development of a live attenuated varicella vaccine. Biken J 1975;18:25-33.
30. Vesikari T, Baer M, Varis T, Chitour K. Efficacy of varicella vaccine is dependent on the virus titer. First World Congress of Pediatric Infectious Diseases, December 4-7 1996, Acupulco, Mexico. Abstract.
31. Meurice F, De Bouver J-L, Vandervoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. J Infect Dis 1996;174:S324-S329.
32. Vesikari T, Varis T, Baer M, Chitour K. A Four-Year Follow-up of Varicella Vaccine Efficacy in Children. 14th Annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), 18-21 June, 1996. Elsinore, Denmark.
33. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996;174(Suppl. 3):S310-S313.
34. Gershon AA, Steinberg SP, LaRussa P, Ferrera A, Hammerschlag M, Gelb L, The NIAIA Varicella Collaborative Study Group. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 1988;158:132-137.
35. Krause P, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 1995;127:518-525.
36. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495-1499.
37. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001;344:59-60.
38. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella vaccine efficacy trial in healthy children. N Engl J Med 1984;310:1409-1415.
39. Tabony L, Kilgore P, Pelosi J et al. Varicella vaccine effectiveness during a child care center outbreak. Travis County, Texas 1998, Paper presented at the 36th Annual Meeting of the Infectious Diseases Society of America: November 12-15, 1998; Denver, Col. Abstract 79.
40. Arbeter AM, Starr SE, Preblud SR, et al. Varicella vaccine trials in healthy children: a summary of comparative and follow-up studies. Am J Dis Children 1984;138:434-438.
41. Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuch K. Clinical experience with Oka live varicella vaccine in Japan. Postgrad Med J 1985;61(Suppl. 4):61-67.
42. MMWR, Prevention of varicella. Update Recommendations of the Advisory Committee in Immunization Practices (ACIP) 1999;48:1-6. No. RR-6.
43. Asano Y, Nagal T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985;75:667-671.
44. WHO. Vaccines, Immunization and Biologicals. Varicella. http://www.who.int?vaccines/intermediate/varicella.htm. (Accessed 1/10/01).
45. Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merk varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-upstudies. Vaccine 1991;9: 643-647.
46. Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for health care workers. Epidemiol Infect 1997;119:209-220.
47. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 1995;95:632-638.
48. Preblud SR, Orens WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985;61(Suppl. 4):17-22.
49. Schuffhan P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Social Sci Med 1999;49:763-779.
50. Schuffhan PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000;18:407-415.
51. Arvin AM. Varicella vaccine-the first six years (editorial). N Engl J Med 2001;344:1007-1009.
52. Strassels SA, Sullivan SD. Clinical and economic considerations of vaccination against varicella. Pharmacotherapy 1997;17:133-139.
53. Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chicken pox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
54. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996;174(Suppl. 3):S33-S41.
55. Brisson M, Edmunds WJ. Cost- Effectiveness of Varicella Vaccination in Canada. Conference on The Economics of Infectious Diseases, London School of Hygiene and Tropical Medicine. 29/30 March 00, London.
56. Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999;17: 142-151.
57. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284: 1271-1279.
58. Kitai JC, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clin Infect Dis 1993;17:441-447.
59. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;12:61-69.
60. Huse DM, Meisner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994;124:869-874.
61. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of reschool children in the United States. Am J Epidemiol 1994;140:81-104.
62. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-3090.
63. Hudeckova H, Straka S, Rusnakova S. Epidemiological feature and economic evaluation of a potential chickenpox vaccination strategy in Slovak Republic. Cent Eur J Public Health 2000;8:227-228.
64. Smith KJ, Roberts MS. Cost-effectiveness of vaccination strategies in adults without a history of chickenpox. Am J Med 2000;108:746-747.
65. Glantz JC, Mushlin AI. Cost-effectiveness of routine antenatal varicella screening. Obstet Gynecol 1998;91: 519-528.
66. Howell MR, Lee T, Gaydos CA, Nang RN. The cost-effectiveness of varicella screening and vaccination in US. Army recruits Mil Med 2000;16:309-311.
67. Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost-effectiveness of using varicella vaccine in healthcare workers. Infect Control Hosp Epidemiol 1997;18:504-508.
68. Habermehl P, Lingitz A, Knuf M, Schmitt H-J, Salaoui M, Zepp F. Cellular immune response to a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 1999;17:669-674.
69. Stuck B, Stehr K, Bock HL, Chitour K, Clemens R. Immunogenicity and reactogenicity of measles-mumps-rubella vaccines at 12-24 months. SB DATA 1997.
70. Arbeter AM, Baker L, Starr SE. Combination measles, mumps, rubella, and varicella vaccine. Pediatrics 1986; 76(Suppl.):742-747.
71. Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgrad Med 1985;61(Suppl. 4): 129-132.
72. Brunell PA, Novelli VM, Lipton S, Pollock B. Combined vaccine against measles, mumps, rubella and varicella. Pediatrics 1988;81:779-784.
73. Berger R, Just M. Interference between strains in live virus vaccines. II. Combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 1988;16: 275-279.
74. Vesikari T, Ohrling A, Baer M, Delem A, Boegaerts H, Andre FE. Evaluation of live attenuated caricella vaccine (Oka-Rit strain) and combined varicella and MMR vaccination in 13-17 month-old children. Acta Paediatr Scand 1991;80:1051-1057.
75. Weibel RE, Kuter BJ, Neff BJ, et al. Live Oka/Merk varicella vaccine in healthy children; further clinical and laboratory assessment. JAMA 1985;154:2435-2439.
76. Central Bureau of Statistics, Statistical Tables on Selected Infectious Diseases 1981-8. Special Series No 826, Jerusalem: CBS; 1988.
77. Somekh E, et al. The burden of uncomplicated cases of chickenpox in Israel. J Infect 2002;45:54-57.
78. Central Bureau of Statistics, Monthly Bulletin of Statistics Sept 2001, vol. 2,.; 2001. No. 8, Oct.
79. Central Bureau of Statistics, Annual Abstract of Statistics 01 No 52. 2001.
80. Joseph C, Naoh H. Epidemiology of chickenpox in England and Wales 1967-1985. BMJ 1988;296:673-676.
81. Centers for Disease Control, Annual Summary 1984: reported morbidity and mortality in the United States. MMWR 1986;33:75-130.
82. Jackson MA, Bunny YB, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Infect Dis J 1992;11:441-445.
83. Pollock JL, Golding J. Social epidemiology of chickenpox in two British national cohorts. J Epidemiol Community Health 1993;47:274-281.
84. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Ped Infect Dis 1984;3:505-509.
85. Guess HA, Broughton DD, Melton LJ, Kurland LT. Chickenpox hospitalizations among residents in Olmstead County, Minnesota, 1962 through 1981: a population-based study. Am J Dis Children 1984;38:1055-1057.
86. Maharshak N, Somekh E. Hospitalization for varicella in Central Israel. Acta Paediatr 1999;88:1279-1283.
87. Somekh E, Maharashak N, Shapira Y, Greenberg D, Dagan R. Hopitalization for primary varicella-zoster virus infection and its complications in patients from Southern Israel. Infection 2000;28:200-204.
88. Ginsberg GM, Silverberg DS. A cost-benefit analysis of legislation for bicycle safety helmets in Israel. Am J Public Health 1994;84:653-656.
89. Expert Panel Conference, Cost-effectiveness of Varicella Vaccine and Acyclovir Use. Atlanta, GA: Centers for Disease Control and Prevention; 1993. January 12.
90. Lieu TA, Black SB, Rieser N. The cost of childhood chickenpox: parent's perspective. Pediatr Infect Dis J 1994;173-177.
91. Demmler GJ, Steinberg SP, Blum G, Gershon AA. Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella zoster virus. J Infect Dis 1988;157: 211-212.
92. Kelley PW, Petrucelli BP, Stehr-Green P, et al. The susceptability of young adult Americans to vaccine preventable infections: a national serosurvey of US Army recruits. JAMA 1991;266:2724-2729.
93. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 2000;18:2775-2778.
94. Anderson RM, May RM. Infectious Disease of Humans. Dynamics and Control, New York: Oxford University Press; 1991.
95. Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003;21:1256-1267.
96. Ferson MJ, Shen WL, Stark A. Direct and indirect costs of chickenpox in young children. J. Paediatr Child Health 1998;34:18-21.
97. Gershon AA. Varicella vaccine: its past, present and future. Pediat Infect Dis J 1995;14:742-744.
98. Lieu TA, Black SB, Shinefield HR, et al. Routine childhood varicella vaccination [letter]. JAMA 1994;271:1906.
99. Law B, Fitzsimon C, Ford-Jones L, et al. Cost of chickenpox in Canada: Part II. Cost of complicated cases and total economic impact. Pediatrics 1999;104:7-14.
100. Paul JE, Mauskopf JA, Bell L. Cost-consequence models for varicella-zoster virus infections. Pharmacotherapy 1991; 15:549S-558S.
101. I&G Infratest and GfK Gesundheis- und Pharmamarkt-Forchung (varicella perception). Nuremberg, Germany: GmbH, July 1993.
102. Canada Communicable Disease Report, Direct costs attributed to chickenpox and herpes zoster in British Columbia-1982 to 1996. CCDC 1999;11(2):102-104.
103. Garnett GP, Grenfell BT. The epidemiology of varicella-zoster-virus infections: the influence of varicella on the prevalence of herpes-zoster. Epidemiol Infect 1992;108: 513-528.
104. Levin MJ, Murray M, Zerbe GO, White CJ, Hayard AR. Immune response of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994;170: 522-524.
105. Zerbom L, Nader S, Aokt K, Arvin AM. Analysis of persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 1998;177:1701-1704.
106. Weller TH. Varicella and herpes zoster: changing concepts of the natural history, control and importance of a not so benign virus. N Engl J Med 1983;309:1362-1368.
107. Gershon A, Silvers S. Live attenuated varicella vaccine for prevention of herpes zoster. Biologicals 1997;25:227-230.
108. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 1991;325:1545-1550.
109. Gershon AA, Steinberg SP, Gelb L, et al. A multicentre trial of a live attenuated varicella vaccine in children with leukemia in remission. Postrad Med 1985;61(Suppl. 4): 73-78.
110. Plotkin SA, Starr SE, Conor K, Morton D. Zoster in normal children after varicella vaccine. J Infect Dis 1989;159: 1000-1001.
111. Gershon AA, Steinberg SP. Live attenuated varicella vaccine protection in healthy adults compared with leukemic children. J Infect Dis 1990;161:661-666.